How Retatrutide Works: GIP, GLP-1 and Glucagon Explained
Retatrutide is designed as one peptide with activity at three metabolic hormone receptors. Understanding the molecule starts by separating what GIP, GLP-1 and glucagon signalling contribute.
Retatrutide is often described as a triple agonist. The phrase is important because the molecule is designed to activate three distinct receptors: the GIP receptor, the GLP-1 receptor and the glucagon receptor. The scientific idea is not simply to add three effects together, but to investigate whether one engineered peptide can coordinate complementary metabolic signals.
GLP-1 receptor signalling
GLP-1 receptor agonism is well established in metabolic research. Signalling through this receptor can influence appetite, food intake, glucose-dependent insulin secretion and gastric emptying. In a multi-receptor molecule, GLP-1 activity provides one part of the metabolic framework rather than the whole explanation.
GIP receptor signalling
GIP is another incretin hormone involved in nutrient-responsive insulin signalling. Retatrutide was engineered from a GIP-related peptide backbone and shows substantial GIP receptor activity. Researchers study GIP together with GLP-1 because the two pathways can interact in ways that differ from activating GLP-1 alone.
Why add the glucagon receptor?
The glucagon receptor makes retatrutide mechanistically different from dual GIP/GLP-1 agonists. Preclinical work on LY3437943 reported that glucagon receptor activation contributed to increased energy expenditure in animal models, while GIP and GLP-1 signalling contributed to reduced energy intake. This finding helped establish the biological rationale for triple-receptor design, although animal mechanisms cannot be assumed to translate quantitatively to humans.
One molecule, deliberately balanced activity
A multi-receptor agonist is not simply three separate drugs mixed together. Retatrutide is a single engineered peptide with a defined activity profile across three receptors. The balance between receptor activities matters because each pathway can influence both desired metabolic effects and tolerability.
Mechanism is not the same as clinical proof
Mechanistic studies explain why a molecule was designed and help researchers interpret trial results. They do not establish clinical benefit by themselves. Retatrutide’s clinical profile has therefore been tested progressively through Phase 1, Phase 2 and Phase 3 studies rather than inferred from receptor biology alone.
Research context: retatrutide remains investigational. This explanation describes receptor pharmacology and does not provide instructions for use.
Related products
See allFrequently asked questions
Why is retatrutide called a triple agonist?
Because one retatrutide molecule is designed to activate GIP, GLP-1 and glucagon receptors.
What makes retatrutide different from a dual GIP/GLP-1 agonist?
The additional glucagon receptor activity is the major mechanistic distinction.
Does glucagon receptor activation only affect blood glucose?
No. Glucagon signalling also influences substrate use and energy metabolism, which is part of the research rationale for including that receptor.
Does knowing the mechanism prove how well retatrutide works clinically?
No. Receptor pharmacology generates and explains hypotheses; controlled clinical trials are needed to establish efficacy and safety.
Sources and further reading
About the author
Synedica Research Desk
Scientific content team
The Synedica Research Desk writes and maintains the technical library behind the Synedica Europe catalogue. The team compiles publicly available literature, supplier documentation and analytical data into plain-language explainers for laboratory and research audiences.
- Reviews certificates of analysis supplied with every Synedica batch
- Sources claims from peer-reviewed literature and regulator publications
- Publishes review dates and correction notes on every article
Continue reading
See all
Retatrutide Phase 3 Results: What the 2026 TRIUMPH Data Show
Retatrutide moved from promising Phase 2 data to multiple positive Phase 3 studies in 2026. Here is what the TRIUMPH results actually show—and what they do not establish yet.
Tirzepatide and Retatrutide: Research Differences
One engages two receptors, the other three. This is what that difference means in research terms — and what remains unknown.
Appetite Signalling and Gut Hormones
Hunger is a signalling problem before it is a willpower problem. Here is the circuitry the literature describes.